Phase I Study to Evaluate rhTPO in Healthy Caucasian Volunteers
- Conditions
- Interventions
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Target Recruit Count
- 22
- Registration Number
- NCT06630494
- Locations
- 🇦🇺
Nucleus Network Pty Ltd., Melbourne, Australia
Safety, Tolerability, and Pharmacokinetic Characteristics of SSS11 in Patients With Gout and Hyperuricemia
- Conditions
- Interventions
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Target Recruit Count
- 60
- Registration Number
- NCT06629376
- Locations
- 🇨🇳
HuaShan Hospital Fudan University project, ShangHai, China, Shanghai, China
Phase III Clinical Study of Recombinant Erythropoiesis Stimulating Protein Injection (rESP) in the Treatment of Anemia in Hemodialysis Patients With Chronic Renal Failure
- First Posted Date
- 2022-01-27
- Last Posted Date
- 2022-01-27
- Lead Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Target Recruit Count
- 300
- Registration Number
- NCT05211167
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
A Phase Ib Clinical Study for rhTPO in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease
- Conditions
- Interventions
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2022-01-14
- Lead Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Target Recruit Count
- 54
- Registration Number
- NCT05193201
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
A Phase 1 Study of SSS17 in Healthy Subjects.
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Target Recruit Count
- 76
- Registration Number
- NCT04893187
- Locations
- 🇨🇳
The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
A Multi-site Bridging Study of Nalfurafine Hydrochloride Orally Disintegrating Tablet
- Conditions
- Interventions
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Target Recruit Count
- 135
- Registration Number
- NCT04728984
- Locations
- 🇨🇳
The First Affiliated Hospital of Medical College of Zhejiang University, Hangzhou, Zhejiang, China
A Study of SSS17 in Healthy Subjects
- First Posted Date
- 2020-03-23
- Last Posted Date
- 2020-03-23
- Lead Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Target Recruit Count
- 65
- Registration Number
- NCT04317833
- Locations
- 🇨🇳
Shanghai Public Health Clinical Center, Shanghai, Shanghai, China
Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP)
- First Posted Date
- 2019-09-13
- Last Posted Date
- 2019-09-13
- Lead Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Target Recruit Count
- 288
- Registration Number
- NCT04089267
- Locations
- 🇨🇳
Xinxiang Central Hospital,, Xinxiang, China
🇨🇳renmin Hospital of Wuhan University Hubei General Hospital, Wuhan, Hubei, China
🇨🇳Loudi Central Hospital, Loudi, Hunan, China
A Study to Determine the Safety, Tolerability, PK and Preliminary PD of SSS11 in Chinese Healthy Adult Volunteers
- First Posted Date
- 2019-08-06
- Last Posted Date
- 2021-07-08
- Lead Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Target Recruit Count
- 33
- Registration Number
- NCT04047394
- Locations
- 🇨🇳
The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Study of rESP Injection for the Treatment of Anemia in Chronic Renal Failure Patients With Hemodialysis
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2020-03-09
- Lead Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Target Recruit Count
- 150
- Registration Number
- NCT03950687
- Locations
- 🇨🇳
The general hospital of the people's liberation army, Beijing, Beijing, China